SFDA registration ahead of iptacopan, not differentiation from entrenched anti-C5 therapy, will decide GCC PNH launch success.

Eculizumab and ravulizumab are entrenched as GCC standard of care, managed by fewer than 10 haematologists concentrated at KFSH&RC Riyadh, the largest GCC PNH cohort at roughly 40 patients, plus KAMC Riyadh, King Abdulaziz Medical City Jeddah, American Hospital Dubai, and Sheikh Shakhbout Medical City Abu Dhabi. NPHC prior-authorisation criteria, a FLAER-confirmed clone of 10% or more, LDH at least twice the upper limit of normal, and a haematology specialist letter, are already established around this anti-C5 baseline and will apply to any new agent. Total GCC PNH patients on treatment are estimated at 150-250, against a broader treated-plus-undertreated population of 500-800.

The commercial opportunity is a closing window. Iptacopan, an oral Factor B inhibitor, received FDA approval in November 2023, with SFDA registration estimated at 18-24 months post-FDA, placing potential approval in 2025-2026. A pre-launch agent that clears SFDA registration before iptacopan enters GCC as the first oral PNH therapy in the region, a first-mover position NPHC may favour on administration-cost grounds. Layered on top is a 40-80 patient extravascular haemolysis cohort, transfusion-dependent despite C5 inhibitor therapy, the clearest unmet-need target if diagnosed. FLAER flow cytometry, the gold-standard clone-size test, is available only at KFSH&RC and a handful of GCC labs.

Whoever files first with SFDA, not whoever differentiates best, wins this window.

Five questions this report answers:

Q1 - Can a new oral PNH agent beat iptacopan to SFDA registration in the GCC?

Q2 - How large is the GCC EVH-inadequate-control cohort, and how is it identified?

Q3 - What NPHC and non-Saudi GCC payer groundwork must start before SFDA approval?

Q4 - What determines whether a pre-launch oral PNH agent succeeds commercially in the GCC?

Q5 - What deliverables and verification standard back every AXLRx GCC PNH assessment?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #GCC #SFDA #RareDisease #LaunchReadiness #Haematology

Live report page:  https://axlrx.ai/pnh/gcc/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-     hello@axlrx.ai

Web-     https://axlrx.ai/